REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04525183

Recruitment Status : Active, not recruiting

First Posted : August 25, 2020

Last Update Posted : September 7, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

AstraZeneca

National Comprehensive Cancer Network

Information provided by (Responsible Party):

Alexi A. Wright, MD, Dana-Farber Cancer Institute

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	July 28, 2022
Estimated Study Completion Date :	December 28, 2023

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	October 12, 2023	April 12, 2024
2	April 22, 2024

To Top